These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 34045817)

  • 1. Off-label Use of Itolizumab in Patients with COVID-19 ARDS: Our Clinical Experience in a Dedicated COVID Center.
    Kumari P; Kumar A; Sinha C; Kumar A; Singh PK; Arun SK
    Indian J Crit Care Med; 2021 Apr; 25(4):467-469. PubMed ID: 34045817
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Itolizumab, an anti-CD6 monoclonal antibody, as a potential treatment for COVID-19 complications.
    Loganathan S; Athalye SN; Joshi SR
    Expert Opin Biol Ther; 2020 Sep; 20(9):1025-1031. PubMed ID: 32700604
    [TBL] [Abstract][Full Text] [Related]  

  • 3.
    Kr R; Rathod C; Darnule R; Loganathan S; Deodhar S; A R; Marwah A; Chaudhari NM; Thakur BK; Vaidyanathan S; Athalye SN
    Expert Opin Biol Ther; 2023 May; 23(5):443-454. PubMed ID: 37073744
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Are We Jumping the Gun with Itolizumab in India? A Situational Analysis from the Pre-COVID Era.
    Thangaraju P; Venkatesan N; Thangaraju E; Venkatesan S
    SN Compr Clin Med; 2020; 2(11):2131-2136. PubMed ID: 33015549
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A two-arm, randomized, controlled, multi-centric, open-label phase-2 study to evaluate the efficacy and safety of Itolizumab in moderate to severe ARDS patients due to COVID-19.
    Kumar S; De Souza R; Nadkar M; Guleria R; Trikha A; Joshi SR; Loganathan S; Vaidyanathan S; Marwah A; Athalye SN
    Expert Opin Biol Ther; 2021 May; 21(5):675-686. PubMed ID: 33835886
    [No Abstract]   [Full Text] [Related]  

  • 6. Itolizumab Treatment for Cytokine Release Syndrome in Moderate to Severe Acute Respiratory Distress Syndrome Due to COVID-19: Clinical Outcomes, A Retrospective Study.
    Gore V; Kshirsagar DP; Bhat SM; Khatib KI; Mansukhani B
    J Assoc Physicians India; 2021 Feb; 69(2):13-18. PubMed ID: 33527804
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of a Humanized Anti-CD6 Monoclonal Antibody (Itolizumab) in Elderly Patients with Moderate COVID-19.
    Díaz Y; Ramos-Suzarte M; Martín Y; Calderón NA; Santiago W; Viñet O; La O Y; Oyarzábal JPA; Pérez Y; Lorenzo G; Cepeda M; Saavedra D; Mazorra Z; Estevez D; Lorenzo-Luaces P; Valenzuela C; Caballero A; Leon K; Crombet T; Hidalgo CJ
    Gerontology; 2020; 66(6):553-561. PubMed ID: 33105142
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Approval of Itolizumab for COVID-19: A Premature Decision or Need of The Hour?
    Atal S; Fatima Z; Balakrishnan S
    BioDrugs; 2020 Dec; 34(6):705-711. PubMed ID: 33048300
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Itolizumab in Psoriasis.
    Srivastava A
    Indian J Dermatol; 2017; 62(4):418-421. PubMed ID: 28794555
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An anti-CD6 monoclonal antibody (itolizumab) reduces circulating IL-6 in severe COVID-19 elderly patients.
    Saavedra D; Añé-Kourí AL; Sánchez N; Filgueira LM; Betancourt J; Herrera C; Manso L; Chávez E; Caballero A; Hidalgo C; Lorenzo G; Cepeda M; Valenzuela C; Ramos M; León K; Mazorra Z; Crombet T
    Immun Ageing; 2020 Nov; 17(1):34. PubMed ID: 33292350
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rationale for treating primary Sjögren's syndrome patients with an anti-CD6 monoclonal antibody (Itolizumab).
    Le Dantec C; Alonso R; Fali T; Montero E; Devauchelle V; Saraux A; Pers JO; Renaudineau Y
    Immunol Res; 2013 Jul; 56(2-3):341-7. PubMed ID: 23576060
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of COVID-19 patients with the anti-CD6 antibody itolizumab.
    Caballero A; Filgueira LM; Betancourt J; Sánchez N; Hidalgo C; Ramírez A; Martinez A; Despaigne RE; Escalona A; Diaz H; Meriño E; Ortega LM; Castillo U; Ramos M; Saavedra D; García Y; Lorenzo G; Cepeda M; Arencibia M; Cabrera L; Domecq M; Estévez D; Valenzuela C; Lorenzo P; Sánchez L; Mazorra Z; León K; Crombet T
    Clin Transl Immunology; 2020; 9(11):e1218. PubMed ID: 33304584
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cytokine Storm and Immunomodulation in COVID-19.
    Rangappa P
    Indian J Crit Care Med; 2021 Nov; 25(11):1288-1291. PubMed ID: 34866828
    [TBL] [Abstract][Full Text] [Related]  

  • 14. T cell activation and differentiation is modulated by a CD6 domain 1 antibody Itolizumab.
    Bughani U; Saha A; Kuriakose A; Nair R; Sadashivarao RB; Venkataraman R; Patel S; Deshchougule AT; S SK; Montero E; Pai HV; Palanivelu DV; Melarkode R; Nair P
    PLoS One; 2017; 12(7):e0180088. PubMed ID: 28672038
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multiple Peaked Cytokine Storm: Is Multiple Exposures to the COVID-19 Virus a Possible Cause?
    Kumar A; Kumar A; Kumar A; Kumar N; Sinha C; Singh V
    Indian J Crit Care Med; 2021 Apr; 25(4):463-464. PubMed ID: 34045815
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dual Oxygen Therapy in COVID-19 Patient: A Method to Improve Oxygenation.
    Kumar A; Kumar A; Sinha C; Kumar N; Singh K; Singh PK
    Indian J Crit Care Med; 2021 Feb; 25(2):231-233. PubMed ID: 33707906
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Itolizumab, a novel anti-CD6 monoclonal antibody: a safe and efficacious biologic agent for management of psoriasis.
    Dogra S; Uprety S; Suresh SH
    Expert Opin Biol Ther; 2017 Mar; 17(3):395-402. PubMed ID: 28064543
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The anti-CD6 antibody itolizumab provides clinical benefit without lymphopenia in rheumatoid arthritis patients: results from a 6-month, open-label Phase I clinical trial.
    Rodríguez PC; Prada DM; Moreno E; Aira LE; Molinero C; López AM; Gómez JA; Hernández IM; Martínez JP; Reyes Y; Milera JM; Hernández MV; Torres R; Avila Y; Barrese Y; Viada C; Montero E; Hernández P
    Clin Exp Immunol; 2018 Feb; 191(2):229-239. PubMed ID: 28963724
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cytokine Storm in Novel Coronavirus Disease (COVID-19): Expert Management Considerations.
    Mehta Y; Dixit SB; Zirpe KG; Ansari AS
    Indian J Crit Care Med; 2020 Jun; 24(6):429-434. PubMed ID: 32863636
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tocilizumab and COVID-19.
    Chaudhry D; Singh PK
    Indian J Crit Care Med; 2020 Sep; 24(9):741-743. PubMed ID: 33132549
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.